Abstract
Background/Aims: Primary adrenal insufficiency (AI) is an important cause of morbidity in children. Our objectives were: (1) to describe the clinical presentation of children with new-onset primary AI, and (2) to identify monogenic causes of primary AI in children. Methods: Chart review and mutation detection in candidate genes were conducted for 11 patients with primary AI. Results: The likely cause of AI was determined in 9 patients. One had a homozygous MC2R mutation associated with familial glucocorticoid deficiency. Two had the same homozygous mutation in the AIRE gene which is associated with type 1 autoimmune polyglandular syndrome. One patient had a heterozygous change in this gene of undetermined significance. Five were homozygous for the previously reported p.R188C STAR mutation causing nonclassic lipoid congenital adrenal hyperplasia, representing the largest cohort of such patients from a single geographic area. In the remaining 2 patients, no clear etiology was identified. Conclusions: We recommend genetic testing for patients who have negative anti-adrenal antibodies or suggestive family history. Diagnosing a genetic etiology can provide information about prognosis and treatment, and is therefore beneficial for patients. Our high proportion of patients with nonclassic lipoid congenital adrenal hyperplasia likely represents a founder effect.
References
1.
Betterle C, Morlin L: Autoimmune Addison's disease. Endocr Dev 2011;20:161-172.
[PubMed]
2.
Ten S, New M, MacLaren N: Clinical Review 130: Addison's disease 2001. J Clin Endocrinol Metab 2001;86:2909-2922.
[PubMed]
3.
Husebye E, Løvås K: Pathogenesis of primary adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009;23:147-157.
[PubMed]
4.
Kong M, Jeffcoate W: Eighty-six cases of Addison's disease. Clin Endocrinol (Oxf) 1994;41:757-761.
[PubMed]
5.
Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003;361:1881-1893.
[PubMed]
6.
Løvås K, Husbye E: High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf) 2002;56:787-791.
[PubMed]
7.
Lin L, Hindmarsh P, Metherell L, Alzyoud M, Al-Ali M, Brain C, Clark A, Dattani M, Acherman J: Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia. Clin Endocrinol (Oxf) 2007;66:205-210.
[PubMed]
8.
Meimaridou E, Hughes CR, Kowalczyk J, Chan L, Clark A, Metherell L: ACTH resistance: genes and mechanisms. Endocr Dev 2013;24:57-66.
[PubMed]
9.
Meimaridou E, Hughes C, Kowalczyk J, Gausti L, Chapple J, King P, Chan L, Clark A, Metherell L: Familial glucocorticoid deficiency: new genes and mechanisms. Mol Cell Endocrinol 2013;371:195-200.
[PubMed]
10.
Meimaridou E, Kowalczyk J, Guasti L, Hughes C, Wagner F, Frommolt P, Nurnberg P, Mann N, Banerjee R, Saka H, Chapple J, King P, Clark A, Metherell L: Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet 2012;44:740-742.
[PubMed]
11.
Prasad R, Chan L, Hughes C, Kaski J, Kowalczyk J, Savage M, Peters C, Nathwani N, Clark A, Storr H, Metherell L: Thioredoxin reductase 2 (TXNRDd2) mutation associated with familial glucocorticoid deficiency (FGD). J Clin Endocrinol Metab 2014;99:E1556-E1563.
[PubMed]
12.
Nagamine K, Peterson P, Scott H, et al: Positional cloning of the APECED gene. Nat Genet 1997;17:393-398.
[PubMed]
13.
Miller W: Congenital lipoid adrenal hyperplasia: the human gene knock-out of the steroidogenic acute regulatory protein. J Mol Endocrinol 1997;19:227-240.
[PubMed]
14.
Baker B, Lin L, Kim C, Raza J, Smith C, Miller W, Achermann J: Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006;91:4781-4785.
[PubMed]
15.
Metherell L, Naville D, Halaby G, Begeot M, et al: Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab 2009;94:3865-3871.
[PubMed]
16.
Statistics Canada: Estimates of Population, Canada, Provinces and Territories. Ottawa, CANSIM Database, 2013.
17.
Senior Citizens of Burin: The History of Burin. Marystown, South Coast Printers, 1977.
18.
Spirio L, Green J, Robertson J, Robertson M, Otterud B, Sheldon J, Howse E, Green R, Groden J, White R, Leppert M: The identical 5′ splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. Hum Genet 1999;105:388-398.
[PubMed]
19.
Olufemi S, Green J, Manickam P, Guru S, Agarwal S, Kester M, Dong Q, Burns A, Spiegel A, Marx S, Collins F, Chandrasekharappa S: Common ancestral mutation in the MEN-1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat 1998;11:264-269.
[PubMed]
20.
Newhook L, Grant M, Sloka S, Hoque M, Paterson A, Hagerty D, Curtis J: Very high and increasing incidence of type 1 diabetes mellitus in Newfoundland and Labrador, Canada. Pediatr Diabetes 2008;9:62-68.
[PubMed]
21.
Clark A, McLoughlin L, Grossman A: Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993;341:461-462.
[PubMed]
22.
Cervato S, Morlin L, Albergoni MP, et al: AIRE gene mutations and autoantibodies to interferon omega in patients with chronic hypoparathyroidism without APECED. Clin Endocrinol (Oxf) 2010;73:630-636.
[PubMed]
23.
Ilmarinen T, Eskelin P, Halonen M, Ruppell T, Kilpikari R, Torres GD, Kangas H, Ulmanen I: Functional analysis of SAND mutations in AIRE supports dominant inheritance of the G228W mutation. Hum Mutat 2005;26:322-331.
[PubMed]
24.
Oftedal B, Hellesen A, Erichsen M, et al: Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune disease. Immunity 2015;42:1185-1196.
[PubMed]
25.
Simm P, McDonnell C, Zacharin M: Primary adrenal insufficiency in childhood and adolescence: advances in diagnosis and management. J Paediatr Child Health 2004;40:596-599.
[PubMed]
26.
Betterle C, Scarpa R, Garelli S, et al: Addison's disease: a survey of 633 patients in Padova. Eur J Endocrinol 2013;169:773-784.
[PubMed]
27.
Fujieda K, Okuhara K, Abe S, Tajima T, Mukai T, Nakae J: Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita. J Steroid Biochem Mol Biol 2003;85:483-489.
[PubMed]
28.
Stocco D: Clinical disorders associated with abnormal cholesterol transport: mutations in the steroidogenic acute regulatory protein. Mol Cell Endocrinol 2002;191:19-25.
[PubMed]
29.
Bhangoo A, Gu W, Pavlakis S, Anhalt H, Heier L, Ten S, Jameson J: Phenotypic features associated with mutations in steroidogenic acute regulatory protein. J Clin Endocrinol Metab 2005;90:6303-6309.
[PubMed]
30.
Chen X, Baker B, Abduljabbar M, Miller W: A genetic isolate of congenital lipoid adrenal hyperplasia with atypical clinical findings. J Clin Endocrinol Metab 2005;90:835-840.
[PubMed]
31.
Flück C, Maret A, Mallet D, Portrat-Doyen S, Achermann J, Leheup B, Theintz G, Mullis P, Morel Y: A novel mutation L260P of the steroidogenic acute regulatory protein gene in three unrelated patients of Swiss ancestry with congenital lipoid adrenal regulatory protein. J Clin Endocrinol Metab 2005;90:5304-5308.
[PubMed]
32.
Sahakitrungruang T, Soccio R, Lang-Muritano M, Walker J, Achermann J, Miller W: Clinical, genetic and functional characterization of four patients carrying partial loss-of-function mutations in the steroidogenic acute regulatory protein (STAR). J Clin Endocrinol Metab 2010;95:3352-3359.
[PubMed]
33.
Baker B, Epand R, Epand R, Miller W: Cholesterol binding does not predict activity of the steroidogenic acute regulatory protein, STAR. J Biol Chem 2007;282:10223-10232.
[PubMed]
34.
Flück C, Pandey A, Dick B, Camats N, Fernández-Cancio M, Clemente M, Gussinyé M, Carrascosa A, Mullis P, Audi L: Characterization of novel star (steroidogenic acute regulator protein) mutations causing non-classic lipoid adrenal hyperplasia. PLoS One 2011;6:e20178.
[PubMed]
35.
Turan S, Hughes C, Atay Z, Guran T, Haliloglu B, Clark A, Bereket A, Metherell L: An atypical case of familial glucocorticoid deficiency without pigmentation caused by coexistent homozygous mutations in MC2R (T152K) and MC1R (R160W). J Clin Endocrinol Metab 2012;97:E771-E774.
[PubMed]
36.
Hsieh S, White PC: Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab 2011; 96:E925-E928.
[PubMed]
37.
Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C: Primary adrenal insufficiency in children: twenty years of experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab 2005;90:3243-3250.
[PubMed]
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
